Cardiometabolic
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
A new review and meta-analysis in Current Atherosclerosis Reports found that non-nutritive sweeteners may not be metabolically inert. Across randomised trials and observational evidence, artificial and low-calorie sweeteners were linked to signals of disrupted glucose-insulin regulation, microbiome changes and higher cardiometabolic risk. The policy problem is not whether sugar is healthy. It is whether “sugar-free”…
Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.
MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
ENDO 2026 reveals the GLP-1 revolution’s real challenge: delivery
Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?
Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
WHO is preparing to ration the obesity drug revolution before it becomes another access disaster
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.